Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors - Wikidata - awgldk - TriplyDB

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

http://www.wikidata.org/entity/Q27658951

about

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples ABL tyrosine kinases: evolution of function, regulation, and specificity Abl family kinases regulate endothelial barrier function in vitro and in mice Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction The Philadelphia chromosome in leukemogenesis Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment Multifunctional Abl kinases in health and disease Critical role of actin-associated proteins in smooth muscle contraction, cell proliferation, airway hyperresponsiveness and airway remodeling Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells Ten things you should know about protein kinases: IUPHAR Review 14 Blind prediction of HIV integrase binding from the SAMPL4 challenge The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class Fluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38α Kinase Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease Completing the structural family portrait of the human EphB tyrosine kinase domains Mechanisms of drug resistance in kinases.Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study Dynamics-Driven Allostery in Protein Kinases Role of ABL family kinases in cancer: from leukaemia to solid tumours Optimizing combination therapies with existing and future CML drugs Allosteric interactions between the myristate- and ATP-site of the Abl kinase p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor Deciphering the structural basis of eukaryotic protein kinase regulation The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1 Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages

P2860

Q24289511-A18C8661-58B9-4CB0-B997-FF75D0A1DBAE Q24299738-808E26CD-E9F7-4194-B33F-689F04DB0991 Q24316240-510A9107-119C-4E03-AF76-04E06B133BB3 Q24622527-3DF4D86D-14ED-48C7-9A7C-FC9DE803C6F6 Q26745531-A39BEF3E-CFCE-40D8-9D1C-64E07E5503FB Q26766299-AA1C23FC-AEF8-4843-91E2-41E0A92B4F78 Q26771277-5C8FB028-2928-466B-924C-7872BB54C95C Q26777713-070D2E71-4CBB-481B-A132-6DF99B3BC6F4 Q26828528-5E2F68BB-E263-4A6D-9E64-351B8C6F95B8 Q26849417-95D07D5E-D6CA-4773-B9D3-F1A0E0C932FB Q26864619-EA9FBACF-FB7A-44D3-B087-99221B38EDC8 Q26866312-A9142549-5E9B-4B32-9DE2-993DAEA18DAA Q27001584-A0B4A7B5-B74E-4817-B182-8BD67ABCAFEA Q27025242-2B1191C4-FA3A-44B1-B385-93013D4A2299 Q27308835-22E2BB91-EB63-40D8-A39C-F0853870662B Q27667290-A5DB98E7-5D26-459F-A117-30067161F89D Q27670655-F9F517EB-9C7E-42C8-883C-3FA0E307F272 Q27675049-8FE6BFE7-1950-4CA6-ABB8-E001E0C1E03E Q27676768-88621EFC-C854-4598-87D4-F6002EA335C1 Q27677124-990C55F2-0B5D-402C-B571-C2D1911AE54B Q27682624-3C071D3A-493A-443C-9743-F08420F015E5 Q27692567-A148155F-31DF-44DD-8FA8-BD60E71A6AA7 Q27698513-569443C9-1FCF-4133-9EDC-68AB8A0D0EF3 Q27852657-1372B1DF-2DD4-4F1E-BFE5-F2195CE2BCAA Q28081279-3E64C0E0-3AA3-4D78-847F-269BE511AF20 Q28396643-4B624912-2E4E-49FA-BEC5-826BB8B87EBD Q28475255-53F15D56-0912-434F-8298-98E869F761F2 Q28476718-15B135C0-0953-47D9-A69A-C330B932B170 Q28478414-448BCD9B-6BB2-41CD-A950-BB36E04B0549 Q28478748-CB7C2D52-BD4D-4784-B03D-C1215AA0BBC4 Q28482070-68B8A9D9-6536-4F55-8A60-8CFFCDBC2B3D Q28482297-D5D4BA59-C69E-47C1-8DE1-DBE559BC7CBB Q28534399-0F4D6F33-CF66-4E31-B68F-3B38703E865C Q28543640-4E8A390C-4B82-4985-A3A2-CFEBC19C585A Q28545055-E77FC120-9AB9-467E-8334-028E0192606A Q28546221-F2F08C07-7EC1-4FCE-8DB0-A2CC77D1FDAF Q28546849-5FCA2349-38E6-4944-83DC-F88A81A4C7D2 Q28550424-F072D624-994B-4D97-A19D-253EFE1D4873 Q28551159-2F83B96E-B6C0-419E-B1A9-56AD4854213D Q28589492-A462D679-E415-4415-BDE3-CDAF56B9B66A

P2860

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

http://www.wikidata.org/entity/Q27658951

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@ast

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@en

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@nl

type

label

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@ast

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@en

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@nl

altLabel

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors

@en

prefLabel

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@ast

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@en

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@nl

P1433

Q27658951-A4275567-7AEA-49D5-8035-18420DA86400

P1476

Q27658951-065994B3-D88B-491C-A430-9F28C55ECB33

P2093

Q27658951-02A223DC-A177-4C1C-A61D-5CCD1D8B25D1

Q27658951-0664F2F2-7699-4731-9EAD-D02BDA2494EC

Q27658951-067FF26F-ED04-41EA-ABAD-4E4E287A4264

Q27658951-0EB0F538-2DA0-4B94-A1B5-293E731D234B

Q27658951-115745AF-BBD7-4979-9F24-C7C8E8B00876

Q27658951-4C8AFDB6-0AA8-459B-A99B-E77FE179C8F2

Q27658951-4F9A1975-7614-43B2-BD28-CF35D1412F3E

Q27658951-53A8D2AC-D333-4510-A0F4-5AC15C8D2F31

Q27658951-55962B10-0595-458B-9398-540F5F9C93EA

Q27658951-599EE71C-C2CE-43FB-BD79-77A945BDF8E4

P2860

Q27658951-0143FD0D-78A3-46E2-AFDD-615B91E026D8

Q27658951-08BC0E08-9F6D-40D7-B024-9A951933CD65

Q27658951-0AC0BBD0-A9CD-4C9E-85A8-276F2110EAAB

Q27658951-11C9D1F2-C5EA-4525-B209-B59942A125E8

Q27658951-1C96F655-D74B-4A1D-B257-9FE8CF25FC9B

Q27658951-1CF1EA2C-19D2-4332-88DB-E36AF856B476

Q27658951-213D6F07-7C8E-4020-BCA3-3D81C8CC7F2E

Q27658951-227AC7AA-EF28-4189-8036-6CB68B62FD6A

Q27658951-27CF89D5-D271-43C4-B373-FDEEA81B0417

Q27658951-2CAB223D-DF11-4423-A094-D49AA32012E9

P2888

Q27658951-9AF8523C-8476-4B81-B24C-4CA2FE9A5F0E

P304

Q27658951-2194D2B0-59F1-4ACB-AD55-265D87F997B7

P31

Q27658951-EA663D30-9E72-4F6B-BC98-6B14780B7C0A

P3181

Q27658951-6070FF78-A53C-4AB5-A65B-4B68FAC41CE3

P356

Q27658951-FB3C0F4D-2EC8-4EF3-9AC6-104529729B99

P407

Q27658951-529AA89B-8081-47F7-93AD-0A80F5115D25

P433

Q27658951-C67CB689-EC4C-4E58-AE63-944D9E5A290A

P478

Q27658951-F5C8E92C-A89C-4CA1-A7D4-625917CF3FB5

P50

Q27658951-21158070-9200-4194-93E3-52A558B957BC

Q27658951-C6CE52C7-3A13-41CD-BE73-70CC3979A836

Q27658951-E1175985-14AA-4F4C-995F-A5A42ED96BE3

P577

Q27658951-A6FE9AD1-C036-4549-A0DC-EA63260B5903

P5875

Q27658951-BDC3B853-5F9A-40BF-94AB-6A34A8E54C36

P6179

Q27658951-3E8A2712-A877-45F8-8450-27ECD5492B8F

P698

Q27658951-D80FAF36-7516-42C1-985E-81AA48DDE6DF

P921

Q27658951-89DEED02-1A89-412B-9DF3-E9A704443AE4

P932

Q27658951-1EBDEBD2-9737-43E6-9A6A-28C1224BDF79

P3181

P356

P1433

P1476

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

@en

P2093

Allen G Li

http://www.w3.org/2001/XMLSchema#string

Amy Wojciechowski

http://www.w3.org/2001/XMLSchema#string

André Strauss

http://www.w3.org/2001/XMLSchema#string

Badry Bursulaya

http://www.w3.org/2001/XMLSchema#string

Barun Okram

http://www.w3.org/2001/XMLSchema#string

Christine Dierks

http://www.w3.org/2001/XMLSchema#string

Fangxian Sun

http://www.w3.org/2001/XMLSchema#string

Francisco J Adrián

http://www.w3.org/2001/XMLSchema#string

Gabriele Fendrich

http://www.w3.org/2001/XMLSchema#string

Gui-Rong Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation

High-speed and high-resolution UPLC separation at zero degrees Celsius

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

Structural basis for the autoinhibition of c-Abl tyrosine kinase

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

Three-dimensional structure of the tyrosine kinase c-Src

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Di- and triphosphopyridine nucleotide isocitric dehydrogenases in yeast

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

P2888

P304

501-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

400710

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE08675

http://www.w3.org/2001/XMLSchema#string

P407

P433

7280

http://www.w3.org/2001/XMLSchema#string

P478

463

http://www.w3.org/2001/XMLSchema#string

P50

Stephan Grzesiek

George Q. Daley

P577

2010-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41013401

http://www.w3.org/2001/XMLSchema#string

P6179

1010126996

http://www.w3.org/2001/XMLSchema#string

P698

20072125

http://www.w3.org/2001/XMLSchema#string

P921

allosteric inhibitor

P932

2901986

http://www.w3.org/2001/XMLSchema#string